PureTech Health is a biotherapeutics company engaged in discovering, developing and commercializing medicines for diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. Co.'s wholly owned pipeline includes therapeutic candidates, such as LYT-100, a clinical therapeutic candidate that it is pursuing for the treatment of a range of conditions involving inflammation and fibrosis and disorders of lymphatic flow; and LYT-200, a clinical immuno-oncology fully human monoclonal antibody candidate targeting a foundational immunosuppressive protein. The PRTC average annual return since 2020 is shown above.
The Average Annual Return on the PRTC average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PRTC average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PRTC average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|